He's been right about VVUS, JAZZ and ARNA so far. His comments are full of common sense. I look forward to him coming back, but it seems to me that he's somewhere else, who knows...
Arena’s Lorqess: A Market Size Analysis [View article]
What I see here is a lot of frustration due to the FDA notes released yesterday. But that's not an excuse to insult or call some people like Joseph and others who are just giving an informed opinion a basher. I´m here to amuse myself and learn, not to get rich. That is not gonna happen playing biotech stocks. So please, longs, If you´ve been so stubborn as not to listen to others opinions and have lost your money because of your mediocrity, have the guts to assume it and learn!!
Is Celldex Therapeutics on the Rebound? [View article]
Celldex will be presenting new data on its lead product CDX-110 at the Society for Neuro-Oncology Scientific Annual Meeting in November 18-21st 2010. I saw Nov 2010 and Feb 2011 in the money calls at a decent price, so I'm considering buying some just in case it pops in the months to come...
Arena's Lorcaserin: Therapeutic Value Zero? [View article]
You got it absolutely right. Lorcaserin's efficacy is not that good...unfortunately for Arena maniacas, that's its strongest reason to get a positive recommendation. I share with you the fact of selling my shares after reading NEJM paper. Why? not only because of poor efficacy, but also because of the statistical method they have used to rule out valvulopathy. It is not as clear as Areniacs (term not mine, but ZZ's) and pumpers alike try to show us. I didn't go short either due to the high price of puts premium, but I'll surely enjoy thursday panel as if it was a football match!! Cheers.
it's hard to say, but the logical thing would be that Jazz would have fallen a bit more and then start a steady trend downwards. Instead of that, Jazz fell 22% to 7.8 or so and today with a general market downtrend, it's come up 2%. As we all have seen this year, the market has been everything but logical and so are biotech stocks. One can't assure what's gonna happen for sure, but simply try to predict what's the most probable scenario and act accordingly.
Should see what? you called me donkey just for commenting on an issue that Xyrem is facing now with the FDA. Now who's the donkey? you bum. Your comments just make me LOL. Where's your money? Let me enjoy your humilliation, poor loser.
Thanks Telsa for sharing your thoughts on JAZZ I learnt a lot. I also agree with howardbaek, we'll see a nice downtrend during next week that will probably bottom around $5.
What Analysts Won't Tell You About Arena [View article]
What Analysts Won't Tell You About Arena [View article]
$2500 to $100,000 blog 2/13 [View instapost]
Arena’s Lorqess: A Market Size Analysis [View article]
What Analysts Won't Tell You About Arena [View article]
Is Celldex Therapeutics on the Rebound? [View article]
Is Celldex Therapeutics on the Rebound? [View article]
Arena's Lorcaserin: Therapeutic Value Zero? [View article]
I share with you the fact of selling my shares after reading NEJM paper. Why? not only because of poor efficacy, but also because of the statistical method they have used to rule out valvulopathy. It is not as clear as Areniacs (term not mine, but ZZ's) and pumpers alike try to show us. I didn't go short either due to the high price of puts premium, but I'll surely enjoy thursday panel as if it was a football match!! Cheers.
$2500 to $100,000 blog 2/13 [View instapost]
A Reintroduction to Savient's Krystexxa [View article]
$2500 to $100,000 blog 2/13 [View instapost]
$2500 to $100,000 blog 2/13 [View instapost]
$2500 to $100,000 blog 2/13 [View instapost]
$2500 to $100,000 blog 2/13 [View instapost]
Jazz FDA Panel Meeting: Leaning on the Positive Outcome Side [View article]